Five sentences. Cited 608 times. The most consequential Written Omission in medical history.
On January 10, 1980, the New England Journal of Medicine published a letter from Jane Porter and Dr. Hershel Jick of Boston University Medical Center. The letter was titled "Addiction Rare in Patients Treated with Narcotics." It was 101 words long. It observed that among hospitalized patients receiving narcotics for pain, the records showed addiction was rare — only four documented cases of "reasonably well documented addiction" out of 11,882 patients who had received at least one narcotic preparation.
Porter and Jick were not studying opioid treatment for chronic pain. They were reviewing records from a hospital database of inpatients receiving monitored short-term doses under clinical supervision. The observation was narrowly valid. The letter was not a study of outpatient chronic pain treatment, extended-release formulations, or the population that would be prescribed OxyContin sixteen years later. The critical qualifier was in the letter. It did not survive the citation process.
The complete text of the Porter-Jick letter, as published in the NEJM:
The letter contains a critical qualifier: "hospitalized medical patients." The population was receiving narcotics under hospital monitoring, typically for acute conditions, for short periods. The addiction rate in this population said nothing about addiction rates in outpatients receiving extended-release opioid formulations for chronic non-cancer pain — the population that would become central to the OxyContin marketing campaign.
The letter's conclusion — "the development of addiction is rare in medical patients with no history of addiction" — was population-specific. "Medical patients" in the hospital context Porter and Jick studied were receiving monitored intravenous or oral doses during brief hospitalizations. The drugs involved — meperidine, Percodan, hydromorphone — were different from OxyContin. The administration context — inpatient monitoring, short courses — was different from outpatient chronic prescribing.
Hershel Jick, interviewed after the letter became prominent in the opioid litigation record, expressed alarm at how it had been used. He stated that the letter was never intended to address outpatient chronic pain prescribing and that its citation as evidence for the safety of that practice was a misapplication. Jane Porter, who had worked with Jick as a medical student, said the letter was "not a study" and that its use in subsequent decades bore no relationship to what she and Jick had actually done.
The letter's 608 citations — documented in a 2017 analysis by Leung et al. in the NEJM that prompted the journal to add an editorial note — were not evenly distributed across time or across citation types. The citation pattern showed a pronounced peak in the 1990s and 2000s, precisely the period during which OxyContin was being marketed for extended use in non-cancer chronic pain.
The Leung analysis found that the critical qualifier — "hospitalized patients" — was omitted in most citations. The letter was typically cited for the proposition that addiction was rare in "patients" treated with opioids for pain, with no qualifier. The omission transformed a narrow clinical observation into a general clinical claim. And the general claim supported a marketing message: opioids prescribed for pain rarely produce addiction.
Purdue Pharma's marketing materials cited the letter or the claim derived from it in training materials, in sales representative talking points, and in materials provided to physicians. The letter was deployed as published evidence for a claim it did not make about a population it did not study.
The 608 citations were not all direct Purdue Pharma citations. The letter had been cited by legitimate clinical researchers, pain specialists, and guideline committees — who then became part of the evidentiary chain that Purdue's marketing could reference. The citation network created an appearance of broad clinical consensus. The appearance was not manufactured by any single actor; it was an emergent property of a citation ecosystem in which the original qualifier had been dropped at the first step and never restored.
The Written Omission mechanism — named in Saga VI for the regulatory and compliance document that omits the step that would have detected the actual outcome — operates through gaps in the evidentiary chain. The Porter-Jick letter is not, itself, a Written Omission. It was a narrow and honest clinical observation. The Written Omission occurred in the citation process: every citation that dropped "hospitalized patients" omitted the step that would have revealed the inapplicability of the observation to the population being prescribed OxyContin.
The missing step is the translation layer: the study or analysis that would have asked whether the hospitalized-patient addiction rate held in outpatient extended chronic-pain prescribing. That study did not exist. It was never funded by Purdue Pharma. It was never required by the FDA as a condition of OxyContin's approval. The marketing message claimed a finding that the evidence did not contain — not through explicit falsification, but through the omission of the qualification that would have revealed the gap.
In June 2017, the New England Journal of Medicine published an editorial note attached to the Porter-Jick letter, written by the editors in response to the Leung et al. analysis. The note stated that the letter had been "heavily and uncritically cited" as evidence that opioid addiction was rare, and that this use "was not supported by the data" in the original letter. The journal did not retract the letter — it was a valid clinical observation of a specific population — but added context making clear that its extensive citation history had misrepresented its scope.
Jick and Porter, by 2017, had both expressed that the letter's use in the opioid epidemic was deeply troubling to them. Neither had anticipated, in 1980, that a brief clinical observation would become the published foundation for a national prescribing expansion. The letter was an honest communication that became a misrepresented one through the citation process — a process that neither author controlled and that operated invisibly in the eighteen years between the letter's publication and OxyContin's launch.
OA-002 documents the KOL network — the physician influence system that disseminated opioid prescribing claims, including claims derived from the Porter-Jick letter, through medical education, conference presentations, and peer-to-peer contact. OA-003 documents the pain-as-vital-sign campaign that created institutional infrastructure requiring pain treatment. Both mechanisms depended on the Five-Sentence Foundation: without published evidence that addiction was rare, the KOL message and the pain metric had no evidentiary anchor.
The Porter-Jick letter was not the cause of the opioid epidemic. It was the epistemic foundation on which the marketing architecture rested. The architecture required a published clinical source for the low-addiction claim. The letter was available. The qualifier was droppable. The gap between what the letter said and what the marketing claimed it said was, for seventeen years, invisible to most of the physicians who cited it and most of the patients who received opioids partly on its basis.
Internal: This paper is part of The Opioid Architecture (OA series), Saga VII. It draws on and contributes to the argument documented across 69 papers in 13 series.
External references for this paper are in development. The Institute’s reference program is adding formal academic citations across the corpus. Priority papers (P0/P1) have complete references sections.